Personal blog of Dr Alex Mendelsohn

Tag: zyban

Bupropion UK supply update: GSK announces the return of Zyban in December 2023

This is an update to a previous post titled: Nearly a year on, Bupropion is still not available

I was worried the previous post might cause confusion to those who came across it hoping for the return of bupropion. Below, I’ve tried to go into a little detail about the potential reasons for the announced return – but please bear in mind I might have easily misinterpreted certain details, and an announcement from a secondary source does not mean resupply is confirmed. I’ve also given an update on the current availability of bupropion in the UK.

UPDATE: Zyban might be back in stock already, GSK‘s medications out-of-stock page has removed Zyban, and the NCSCT has put a notice up on October 16th saying that Zyban is back in stock and being supplied – check with your local pharmacy to confirm if this is in fact true.

UPDATE #2: GSK‘s medications out-of-stock page now says that Zyban will return in late November 2023


So, a notice popped up about a week ago in the form of an exclusive article by David Lipanovic of the Pharmaceutical Journal. It announced that bupropion will once again be supplied to the UK starting around December 2023.

Continue reading

The pharmaceutical industry just stopped producing the only antidepressant that has worked for me

The blog post discusses the recent stoppage of the production of Bupropion (Zyban) and Varenicline (Champix) due to the detection of impurities that could increase the risk of cancer. Alex, who suffers from chronic depression, argues that the benefits of the antidepressant outweigh the minimal risk of cancer. Alex also criticizes the lack of availability of alternative treatments for depression and smoking cessation, particularly MAOIs and the lack of supply of smoking cessation drugs in the UK. Alex questions the logic of discontinuing acute treatments for smoking cessation due to a small risk of cancer over a few months.


Imagine the scenario. Potential impurities are found in some HIV retroviral drugs that produce a small increase in the probability of contracting cancer over their lifetime. I think the last thing you would expect would be the immediate stoppage of the production of the antiretroviral drugs in question. Leaving a patient vulnerable to imminent death as HIV progresses to AIDS is of greater importance than a tiny increase in lifetime cancer risk.

Yet, in the world of mental health treatment, this type of scenario has recently unfolded with the stoppage of the supply of Bupropion (Zyban) in the UK, leaving me and many others without the drug keeping them out of depression.

Continue reading